Allarity Therapeutics (ALLR) boosts cash to $27M but posts larger Q2 2026 loss

Rhea-AI Filing Summary

Allarity Therapeutics, Inc. reported second-quarter 2026 results and development progress for stenoparib, its dual PARP/tankyrase inhibitor for cancer. For the quarter ended June 30, 2026, the company generated no revenue and recorded a net loss of $3.4 million, compared with $2.3 million a year earlier, as other income swung to a net expense. Total operating expenses fell to $2.7 million from $4.1 million, reflecting lower research and development and general and administrative costs.

At June 30, 2026, Allarity held $17.0 million in cash and $10.0 million in restricted cash, with total assets of $32.1 million. Total liabilities rose to $28.6 million, driven largely by a new short-term promissory note of $20.9 million, reducing stockholders’ equity to $3.5 million. Operationally, the company completed a Phase 3-ready stenoparib manufacturing campaign, obtained CLIA certification for its in-house DRP companion diagnostic laboratory, and highlighted a newly granted U.S. patent extending stenoparib DRP exclusivity into 2042.

Positive

• Operating expenses reduced significantly: Q2 2026 total operating expenses fell to $2.7 million from $4.1 million, driven by lower research and development and general and administrative costs.
• Stronger cash position: Cash increased to $17.0 million and restricted cash to $10.0 million, for $27.0 million in total cash and restricted cash at June 30, 2026.
• Key patent protection extended: A U.S. patent covering the stenoparib-specific DRP companion diagnostic provides exclusivity for developing stenoparib with its DRP into April 2042.
• Late-stage readiness improved: Completion of a Phase 3-ready stenoparib manufacturing campaign secures drug supply for planned pivotal, registrational trials.
• CLIA-certified diagnostics capacity: The company obtained CLIA certification for its in-house laboratory, enabling full control of DRP testing to support U.S. clinical trials.

Negative

• Net loss increased: Q2 2026 net loss widened to $3.4 million from $2.3 million, despite lower operating expenses, due mainly to higher interest expense and less favorable other income.
• Leverage rose sharply: Total liabilities climbed to $28.6 million from $8.4 million, including a new short-term promissory note of $20.9 million, while stockholders’ equity declined to $3.5 million.
• Higher interest burden: Quarterly interest expense increased to $0.7 million from $0.0 million–$0.1 million levels a year earlier, reflecting new debt obligations.
• Ongoing operating losses and deficit: Accumulated deficit grew to $136.4 million, and the company remains loss-making with no recurring revenue in the quarter.

Filing Explained

At June 30, 2026, the company’s cash balance equaled 596.1 days of the last reported quarterly operating cash use, providing a historical liquidity comparison rather than a stated future funding period.

Sources and calculations

• Allarity Therapeutics Form 8-K and Exhibit 99.1 (2026-08-14)
• Allarity Therapeutics second-quarter 2026 fundamentals (2026-06-30)

• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $16,982,000 / ($2,564,000 / 90) = [object Object]

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Net loss Q2 2026: $3,405 thousand Net loss Q2 2025: $2,320 thousand Total operating expenses Q2 2026: $2,671 thousand +5 more

8 metrics

Net loss Q2 2026 $3,405 thousand Three months ended June 30, 2026 net loss

Net loss Q2 2025 $2,320 thousand Three months ended June 30, 2025 net loss for comparison

Total operating expenses Q2 2026 $2,671 thousand Three months ended June 30, 2026 operating expenses

Cash balance $16,982 thousand Cash as of June 30, 2026

Restricted cash $9,999 thousand Restricted cash as of June 30, 2026

Total liabilities $28,579 thousand Liabilities as of June 30, 2026

Short-term promissory note $20,862 thousand Promissory note, short term, net of discounts at June 30, 2026

License revenue H1 2026 $25 thousand Six months ended June 30, 2026 license revenue

Key Terms

CLIA certification, companion diagnostic, Phase 3-ready, convertible promissory notes, +2 more

6 terms

CLIA certification medical

"Obtained CLIA certification for its in-house laboratory, enabling full control of DRP testing"

A CLIA certification is a U.S. federal approval that a laboratory must have to perform tests on human samples for diagnosis or monitoring. Think of it as a driver’s license for medical labs: it proves the lab meets standards for accuracy, reliability and quality control. Investors care because having or lacking CLIA certification affects a lab’s legal ability to generate test-related revenue, qualify for reimbursements, form partnerships, and avoid fines or shutdowns.

companion diagnostic medical

"stenoparib-specific DRP companion diagnostic, providing exclusivity to develop stenoparib with its DRP"

A companion diagnostic is a medical test designed to identify which patients are likely to benefit from a specific drug or medical treatment, much like a key that shows whether a particular lock will open. For investors, these tests matter because they can increase a drug’s chances of approval and market uptake, create a separate revenue stream, and reduce commercial risk by matching treatments to the patients most likely to respond.

Phase 3-ready medical

"completed our manufacturing campaign for stenoparib, securing drug supply in accordance with the more stringent standards required for late-stage clinical development"

A drug or medical product described as "phase 3-ready" has completed early human testing and preclinical work and meets the scientific and regulatory conditions to begin large, late-stage clinical trials that measure effectiveness and safety in many patients. For investors this is a major milestone because phase 3 trials are the last, most expensive step before possible regulatory approval and market launch—think of it like a prototype that has passed initial crash tests and is cleared for full production testing.

convertible promissory notes financial

"Convertible promissory notes and accrued interest | | | 1,424"

A convertible promissory note is a loan a company takes that can later be turned into shares instead of being paid back in cash; think of lending money now in exchange for a voucher that can become ownership later. Investors care because it mixes credit risk and potential ownership upside—it can protect lenders if a company struggles while also diluting existing shareholders when converted, affecting future share value and investor returns.

derivative liability financial

"Promissory note - short term, net of discounts | | | 20,862 ... Derivative liability | | | 128"

A derivative liability is an obligation a company owes because of a derivatives contract—such as an option, future, swap, or forward—that has moved against it and now has negative value. Think of it like a settled bet that turned into a bill: if market moves go the other way, the company may have to pay cash or deliver assets. Investors care because these liabilities can create sudden losses, add leverage or counterparty risk, and change a company’s true financial exposure beyond its everyday operations.

par value financial

"Common stock, $0.0001 par value (250,000,000 shares authorized)"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

Earnings Snapshot

Net loss (Q2 2026 vs Q2 2025): $3,405 thousand vs $2,320 thousand

Three and six months ended June 30, 2026

Net loss (Q2 2026 vs Q2 2025) $3,405 thousand vs $2,320 thousand Net loss increased year-over-year

Total operating expenses (Q2 2026 vs Q2 2025) $2,671 thousand vs $4,133 thousand Operating expenses decreased year-over-year

Cash and restricted cash at June 30, 2026 $26,981 thousand combined Higher than December 31, 2025 cash only balance of $14,687 thousand

Total liabilities at June 30, 2026 vs December 31, 2025 $28,579 thousand vs $8,430 thousand Liabilities increased with new short-term promissory note

FAQ

How did Allarity Therapeutics (ALLR) perform financially in Q2 2026?

Allarity recorded a Q2 2026 net loss of $3.4 million on no revenue, compared with a $2.3 million net loss a year earlier. Total operating expenses declined to $2.7 million from $4.1 million, but higher interest expense and other items increased the overall loss.

What was Allarity Therapeutics’ (ALLR) cash position as of June 30, 2026?

As of June 30, 2026, Allarity held $17.0 million in cash and $10.0 million in restricted cash, totaling about $27.0 million. Total assets were $32.1 million, providing resources to continue advancing stenoparib and related clinical programs.

How much debt and liabilities does Allarity Therapeutics (ALLR) have after Q2 2026?

Total liabilities were $28.6 million at June 30, 2026, up from $8.4 million at year-end 2025. This includes a new short-term promissory note of $20.9 million and convertible promissory notes and accrued interest of $1.4 million.

What key patent milestone did Allarity Therapeutics (ALLR) report for stenoparib?

The company reported that the USPTO granted a key U.S. patent covering its stenoparib-specific DRP companion diagnostic, providing exclusivity to develop stenoparib with its DRP into April 2042, strengthening stenoparib’s long-term intellectual property position.

What clinical and manufacturing progress did Allarity Therapeutics (ALLR) highlight?

Allarity completed a Phase 3-ready stenoparib manufacturing campaign, securing late-stage drug supply, and obtained CLIA certification for its in-house DRP laboratory. Ongoing Phase 2 trials include advanced ovarian cancer and relapsed small cell lung cancer programs.

Did Allarity Therapeutics (ALLR) generate any revenue in Q2 2026?

Allarity reported no revenue for Q2 2026, the same as the prior-year quarter. For the first six months of 2026, it recognized $25,000 in license revenue, underscoring its current reliance on financing rather than product sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/14/2026 - 04:40 PM Accepted by SEC EDGAR 08/14/2026 - 04:35 PM Learn about SEC filing dates

false 0001860657 0001860657 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2026

ALLARITY THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41160		87-2147982
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

123 E Tarpon Ave,

Tarpon Springs, FL 34689

(Address of principal executive offices)

(401) 426-4664

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ALLR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information contained in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 14, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Allarity Therapeutics, Inc.
Dated: August 14, 2026
By:	/s/ Thomas H. Jensen
	Thomas H. Jensen
	Chief Executive Officer

2 

Exhibit 99.1

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

- Completed quarter with $26.9 million in cash and restricted cash

- Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP^® companion diagnostic into 2042

- AACR 2026 data linked higher stenoparib DRP^® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP^®-guided patient selection

- Obtained CLIA certification for its in-house laboratory, enabling full control of DRP^® testing to accelerate and support U.S. clinical trials

TARPON SPRINGS, Fla., AUGUST 14, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2026.

“The second quarter was a highly productive period for Allarity. During the quarter, the USPTO granted the key U.S. patent covering our stenoparib-specific DRP® companion diagnostic, providing exclusivity to develop stenoparib with its DRP® into April 2042. This establishes a critical, long-term intellectual property foundation for stenoparib development and commercialization and reinforces our confidence in the long-term potential of our approach to pairing anticancer therapeutics with drug-specific companion diagnostics,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics.

“Subsequent to quarter-end, we also successfully completed our manufacturing campaign for stenoparib, securing drug supply in accordance with the more stringent standards required for late-stage clinical development. Completion of this campaign represents an important step as we prepare for a pivotal, registrational trial. We have also secured CLIA certification for our in-house laboratory, enabling us to do all of the necessary testing for the DRP® in-house, which will further secure our ability to control and accelerate the advance of stenoparib toward FDA approval. I am particularly proud of these accomplishments as they position the company to drive stenoparib forward as rapidly as possible. Together with the presentation of our promising, durable Phase 2 clinical benefit data in advanced ovarian cancer patients at leading international oncology conferences, these achievements further strengthen the foundation for accelerating stenoparib toward FDA approval. Finally, I am pleased that we ended the quarter with almost $27 million in cash and restricted cash, providing us with the financial resources to continue the important work of advancing stenoparib.”

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 1 of 8

Clinical and Drug Development Progress

● Phase 3 manufacturing campaign milestone: During the second quarter, Allarity announced that its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib was progressing in line with the planned timeline at its world-class contract development and manufacturing organization (CDMO). Subsequent to quarter-end, the campaign was successfully completed (July 2026), ahead of the originally planned completion by the third quarter of 2026. The campaign supports accelerating stenoparib toward FDA approval following its FDA Fast Track designation and was completed in anticipation of the generation of clinical benefit data from the ongoing Phase 2 trial in advanced ovarian cancer. All manufacturing-related payments were completed during the second quarter and are recorded as prepaid expenses, and no additional cash outlays for API manufacturing are anticipated.

● Key U.S. patent granted for the stenoparib DRP® companion diagnostic: The United States Patent and Trademark Office (USPTO) granted the key U.S. patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, with a term extending into April 2042. The grant follows the USPTO’s Notice of Allowance announced in April 2026. The patent covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles derived from tumor samples, as well as methods for selecting patients most likely to benefit from stenoparib treatment, and affords commercial exclusivity protection for stenoparib when used in concert with the stenoparib DRP®.

● AACR 2026 data linking DRP® to enhanced overall survival in ovarian cancer: At the American Association for Cancer Research Annual Meeting 2026 (AACR 2026), Allarity presented Phase 2 clinical data showing extended overall survival benefit in advanced, platinum-resistant and refractory ovarian cancer patients, particularly in those patients whose tumors have the highest stenoparib DRP® scores. These data reinforce the value of leveraging the DRP-based patient selection strategies to select patients most likely to benefit from stenoparib and to accelerate stenoparib’s advance to FDA approval.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 2 of 8

● AACR 2026 data highlighting stenoparib’s potential in colorectal cancer: In a second AACR 2026 poster, the Company presented new findings demonstrating stenoparib’s mechanism of action—modulating the WNT/β-catenin signaling pathway and inhibiting the growth of human colorectal cancer cell lines at clinically relevant concentrations. The majority of colorectal cancers activate the WNT pathway, enabling cancer progression and metastatic spread. Accordingly, inhibition of the WNT pathway may provide an exciting new therapeutic option for colon and rectal cancers, which remain among the most prevalent and deadly cancers in the United States.

● Poster presented at ESMO Gynaecological Cancers Congress: Allarity presented a Trial-in-Progress poster outlining the scientific background, study design, and clinical rationale for its ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The poster was presented by the study’s Principal Investigator, Kathleen N. Moore, M.D., an internationally recognized specialist in gynecologic oncology and a leading expert in advanced platinum-resistant and platinum-refractory ovarian cancer.

● Ovarian cancer program continued under FDA Fast Track designation: Allarity continued enrollment in its Phase 2 clinical trial protocol evaluating stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. The amended protocol is designed expressly to capitalize on the emerging clinical experience with stenoparib in platinum-resistant patients and to accelerate the clinical development of stenoparib toward FDA approval.

● SCLC combination trial continued enrollment: The Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC)—fully funded by the U.S. Department of Veterans Affairs (VA)—continued enrolling patients across multiple VA medical centers throughout the United States.

● CLIA certification obtained: Allarity obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA) for its in-house laboratory in Hørsholm, Denmark. The FDA requires that biomarker testing used to select patients for registration trials be performed in a CLIA-certified laboratory environment. For the first time, Allarity is now able to perform its DRP® testing in-house in a CLIA-certified environment to support U.S. clinical trials, including a registrational trial of stenoparib in advanced ovarian cancer. This is expected to reduce reliance on external laboratories, may shorten turnaround times and reduce costs. It also may position the Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified laboratory partner in Northern Europe for other companies seeking to conduct clinical trials in, or commercialize products for the U.S. market.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 3 of 8

Corporate and Strategic Developments

● Scientific visibility at Precision Medicine Forum Europe 2026: CEO Thomas Jensen presented at Precision Medicine Forum Europe 2026 in Stockholm, Sweden, discussing stenoparib’s dual mechanism of action and Allarity’s predictive biomarker, as well as the Company’s ongoing Phase 2 trials.

Second Quarter 2026 Financial Review

Results of Operations for the Three Months Ended June 30, 2026

● Cash Position: As of June 30, 2026, cash and restricted cash totaled $26.9 million, compared to $14.7 million as of June 30, 2025. The Company used $2.6 million of cash in operating activities during the quarter.

● R&D Expenses: Research and development (R&D) expenses were $1.3 million for the quarter ended June 30, 2026, compared to $2.3 million for the quarter ended June 30, 2025.

● G&A Expenses: General and administrative (G&A) expenses were $1.3 million for the quarter ended June 30, 2026, compared to $1.8 million for the quarter ended June 30, 2025.

● Total Comprehensive Loss: The total comprehensive loss attributable to common stockholders was $3.7 million for the quarter ended June 30, 2026, compared to $4.2 million for the quarter ended June 30, 2025. For the six months ended June 30, 2026, the loss was $6.5 million, compared to $7.2 million for the six months ended June 30, 2025.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 4 of 8

About Stenoparib/2X-121

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers, especially drug-resistant cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer, small cell lung cancer and colorectal cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. Allarity has completed its first Phase 2 trial for stenoparib in advanced ovarian cancer patients. That trial showed promising and durable clinical benefit in ovarian cancer patients who had two or more lines of prior lines of therapy and recieved stenoparib twice daily. The updated data from this study were presented at the AACR special conference on advances in ovarian cancer in September 2025. These analyses are subject to change as follow-up matures. A new protocol was designed expressly to capitalize on this emerging clinical experience with stenoparib in platinum-resistant patients and began enrolling patients in the summer of 2025. This amended protocol enrolls only platinum- resistant or platinum-ineligible patients and is designed to accelerate the clinical development of stenoparib toward FDA approval. In parallel, a separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer (SCLC) began enrolling patients in early 2026 and is currently enrolling patients across multiple VA sites in the U.S.

About the Drug Response Predictor – DRP^® Companion Diagnostic

Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which Allarity believes may be useful in all cancer types and is patented for dozens of anticancer drugs, has been extensively published in the peer-reviewed literature.

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 5 of 8

About Allarity Therapeutics

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark and its U.S. business address is in Florida. The Company is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.

Follow Allarity on Social Media

LinkedIn: https://www.linkedin.com/company/allaritytx/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the Company’s ongoing and planned clinical development of stenoparib; the enrollment, conduct, timing and potential results of its Phase 2 trials in advanced ovarian cancer and relapsed small cell lung cancer; the potential safety, efficacy, tolerability and clinical benefit of stenoparib; the potential use of the stenoparib DRP® companion diagnostic for patient selection; the advancement of stenoparib toward pivotal development, FDA approval and commercialization; the availability of drug supply from the completed manufacturing campaign; the anticipated benefits of the Company’s CLIA-certified laboratory; the potential commercial use of the DRP® platform and laboratory services; the scope and duration of patent protection for stenoparib and the stenoparib DRP® companion diagnostic; and the Company’s anticipated cash runway and ability to fund its operations and development plans. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to clinical development, patient enrollment, trial execution and regulatory review; the possibility that clinical results may not demonstrate the anticipated safety, efficacy, durability or clinical benefit of stenoparib; the predictive accuracy, validation, regulatory acceptance and clinical utility of the stenoparib DRP® companion diagnostic; the Company’s ability to obtain, maintain and enforce intellectual property protection; the quality, availability and regulatory compliance of stenoparib drug supply; the Company’s ability to maintain its CLIA certification and other required laboratory approvals; the possibility that anticipated efficiencies, cost savings or commercial opportunities may not be realized; reliance on third-party clinical sites, investigators, manufacturers and suppliers; and the Company’s ability to maintain sufficient financial resources and obtain additional funding, if required. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2026, available at the SEC’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

###

Company Contact:

investorrelations@allarity.com

Media Contact:

Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 6 of 8

ALLARITY THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for share and per share data)

		June 30,				December 31,
		2026				2025
		(Unaudited)
ASSETS
Current assets
Cash		$	16,982			$	14,687
Restricted Cash			9,999				—
Other current assets			61				265
Prepaid expenses			3,377				2,110
Tax credit receivable			1,310				866
Total current assets			31,729				17,928
Non-current assets:
Property, plant and equipment, net			386				330
Total assets		$	32,115			$	18,258
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable		$	4,113			$	4,282
Accrued expenses and other current liabilities			1,971				2,667
Income taxes payable			81				81
Promissory note - short term, net of discounts			20,862				—
Derivative liability			128
Convertible promissory notes and accrued interest			1,424				1,400
Total current liabilities			28,579				8,430
Total liabilities			28,579				8,430
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value (250,000,000 shares authorized); 19,124,363 and 19,030,619 shares issued and 15,910,724 and 16,080,980 outstanding at June 30, 2026 and December 31, 2025, respectively			3				3
Additional paid-in capital			144,683				144,233
Accumulated other comprehensive loss			(1,346	)			(1,021	)
Accumulated deficit			(136,352	)			(130,197	)
Treasury stock, at cost; 3,213,639 and 2,949,639 shares at June 30, 2026, and December 31, 2025, respectively			(3,452	)			(3,190	)
Total stockholders’ equity			3,536				9,828
Total liabilities and stockholders’ equity		$	32,115			$	18,258

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 7 of 8

ALLARITY THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(in thousands, except for share and per share data)

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2026				2025				2026				2025
Revenue:
License Revenue		$	—			$	—			$	25			$	—
Total revenue			—				—				25				—
Operating expenses:
Research and development			1,345				2,321			$	2,642			$	3,724
General and administrative			1,326				1,812				2,742				3,445
Total operating expenses			2,671				4,133				5,384				7,169
Loss from operations			(2,671	)			(4,133	)			(5,359	)			(7,169	)
Other income (expense):
Interest income			217				237				380				459
Interest expense			(719	)			(12	)			(948	)			(69	)
Foreign exchange gains (losses)			(104	)			1,588				(100	)			1,726
Change in fair value of derivative and warrant liabilities			(128	)			—				(128	)			1
Total other income (expense), net			(734	)			1,813				(796	)			2,117
Net loss		$	(3,405	)		$	(2,320	)		$	(6,155	)		$	(5,052	)
Net loss per common share, basic and diluted		$	(0.21	)		$	(0.15	)		$	(0.39	)		$	(0.38	)
Weighted average common shares outstanding, basic and diluted			15,910,724				15,543,321				15,944,946				13,357,266
Other comprehensive loss
Net loss		$	(3,405	)		$	(2,320	)		$	(6,155	)		$	(5,052	)
Change in cumulative translation adjustment			(267	)			(1,830	)			(325	)			(2,106	)
Total comprehensive loss		$	(3,672	)		$	(4,150	)		$	(6,480	)		$	(7,158	)

Allarity Therapeutics, Inc. | 123 E Tarpon Ave | Tarpon Springs, Florida | U.S.A. | NASDAQ: ALLR | www.allarity.com

Page 8 of 8

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 PRESS RELEASE, DATED JUNE 30, 2026 86.9 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB